Expert Ratings for FibroGen
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on FibroGen (NASDAQ:FGEN) stock. The company has an average price target of $4.75, representing a 75.32% decrease from the previous average price target of $19.25. The analysts' ratings are mixed, with 2 being indifferent, 1 somewhat bearish, and 1 bearish.
August 08, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mixed analyst ratings and a significantly lower price target could impact FibroGen's stock negatively in the short term.
Analyst ratings are a significant factor that investors consider when making investment decisions. The mixed ratings and significantly lower price target suggest that analysts have a negative outlook on FibroGen, which could lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100